-Myofilament dysfunction is a common point of convergence for many forms of heart failure. Recently, we showed that cardiac overexpression of PKCε initially depresses myofilament activity and then leads to a progression of changes characteristic of human heart failure. Here, we examined the effects of PKCε on contractile reserve, Starling mechanism, and myofilament activation in this model of end-stage dilated cardiomyopathy. Pressure-volume loop analysis and echocardiography showed that the PKCε mice have markedly compromised systolic function and increased end-diastolic volumes. Dobutamine challenge resulted in a small increase in contractility in PKCε mice but failed to enhance cardiac output. The PKCε mice showed a normal lengthdependent tension development in skinned cardiac muscle preparations, although Frank-Starling mechanism appeared to be compromised in the intact animal. Simultaneous measurement of tension and ATPase demonstrated that the maximum tension and ATPase were markedly lower in the PKCε mice at any length or Ca 2ϩ concentration. However, the tension cost was also lower indicating less energy expenditure. We conclude 1) that prolonged overexpression of PKCε ultimately leads to a dilated cardiomyopathy marked by exhausted contractile reserve, 2) that PKCε does not compromise the FrankStarling mechanism at the myofilament level, and 3) that the Starling curve excursion is limited by the inotropic state of the heart. These results reflect the significance of the primary myofilament contractilopathy induced by phosphorylation and imply a role for PKCε-mediated phosphorylation in myofilament physiology and the pathophysiology of decompensated cardiac failure.
pressure-volume loops; cardiac myofilaments HEART FAILURE IS AN EPIDEMIC of global proportions. Accordingly, vigorous investigation is ongoing to define the cellular events that lead to end-stage cardiac failure. The evidence to date suggests that alterations that occur in response to increased cardiac demand are initially sufficient to maintain adequate cardiac output (CO). However, these changes ultimately prove insufficient in the face of sustained hemodynamic load and, in many cases, exacerbate the progression to decompensated cardiac failure. The upregulation of protein kinase C (PKC) isoforms is a well-documented alteration in cellular signaling that occurs during the progression to failure (2) . Whether this change in kinase activity is employed as a compensatory mechanism is an open question. While several isoforms of PKC have been identified, accumulating evidence indicates that the Ca 2ϩ -independent isoforms (␦ and ε) affect contractile function directly through myofilament phosphorylation (11, 13, 16, 17) . We recently showed in a murine model that PKCε-mediated phosphorylation, when upregulated or unchecked, first results in altered myofilament calcium sensitivity and then subsequently leads to a series of molecular, cellular, and morphological alterations that mimic the progression of human failure (8) . Evaluating the energetic features of the myofilament contractilopathy inherent in the PKCε mice could provide insight into the characteristics of dilated cardiomyopathy (DCM) in general.
The two principal ways by which the heart augments CO from beat-to-beat are increases in activation of the ␤-adrenergic system and changes in end-diastolic volume (EDV), the so-called Frank-Starling (F-S) mechanism (25) . Both mechanisms employ cellular effectors that converge on the myofilaments. For that reason, the state of myofilament activity could reasonably affect both mechanisms. There is a general consensus that there are important changes in the adrenergic signaling during failure, including membrane-associated changes in the ␤-adrenoceptor and intracellular signaling cascades (7) . On the other hand, the role of the F-S mechanism during the progression to failure is debated. Some investigators report normal Starling function in human heart failure (24) , whereas others show substantial compromise in this intrinsic function of the heart (10) . The impact that a primary myofilament contractilopathy would have on the effects of inotropic stimulation and the intrinsic F-S mechanism in this model of end-stage dilated cardiac failure was examined here. How PKCε-mediated phosphorylation of myofilament proteins also affects the efficiency of contraction was also examined here and may provide insight into its physiological role.
MATERIALS AND METHODS
Transgenic animals. The experiments were approved and conducted in accordance with the Institutional Animal Care and Use Committee and National Institutes of Health (NIH) guidelines. Cardiac-specific expression of the constitutively active (i.e., point mutation A159E) PKCε cDNA was driven by a mouse ␣-myosin heavy chain (MHC) promoter on an FVB/N background and as previously described (8) . Mice were genotyped using PCR with primers specific for the rabbit sequence (forward) 5Ј-GATACCCTTACGACGTCC and (reverse) 5Ј-CACATCAGTGACGAATTCGTCG. Crosses were established to produce homozygous offspring with respect to the transgene, of which 12-mo-old males were used.
Pressure-volume loop analysis. All experiments were carried out according to the guidelines proscribed by the Animal Care Committee at the University of Illinois (Chicago). Anesthesia was induced by inhalation with methoxyflurane in a closed chamber. Animals were then intubated. An appropriate plane of anesthesia was maintained with 0.75-1.25% isoflurane through a vaporizer with 100% oxygen connected to a ventilator as previously described (8) . A 1.4-Fr pressure-conductance catheter (Millar Instruments, Houston, TX) was then retrogradely inserted into the left ventricle (LV) across the aortic valve and steady-state pressure-volume loops and hemodynamics were recorded (ARIA-Millar Instruments). After stabilization, the end-systolic pressure-volume relationship and its slope (E max) were derived by varying EDVs. The EDV was selectively altered by intermittent occlusion of the inferior vena cava (IVC) to avoid reduction in thoracic pressure, as previously described. Briefly, a midline incision through the linea alba exposed the falciform ligament, which was dissected to expose the subdiaphragmatic IVC. Intermittent occlusion of the IVC was accomplished using suture ligature and a short segment (ϳ4 mm) of PE-50 tubing. On average, 10 -20 loops were analyzed using the customized software from PVAN (Millar Instruments). Pressure-volume loops were also recorded during an inotropic challenge using intraperitoneal bolus injection of dobutamine (Dob; 250 -300 l of 2.5 M). Acute saturation of the receptors was inferred by lack of further hemodynamic response to additional Dob injection. Representative loops are shown.
Economy of tension and the Ca 2ϩ -tension relationship. Simultaneous tension-ATPase activity at short (1.95 m) and long (2.15 m) sarcomere length (SL) was measured, as previously detailed (5, 22) . The normalized Ca 2ϩ -tension and Ca 2ϩ -ATPase relations at both SLs were obtained as previously described (15) . Briefly, mice were anesthetized with pentobarbital sodium (50 mg/kg body wt), and the hearts were rapidly excised and placed into ice-cold high-relaxing (HR) solution containing (in mM) 20 EGTA, 10 creatine phosphate, 100 BES, 5.93 ATP, 6.6 magnesium chloride, 20.7 potassium proprionate, at pH 7.0, 10 IU/ml creatine kinase (bovine heart, Sigma) and 0.5 mM DTT. The total ionic strength of HR was 200 mM. A cocktail of protease inhibitors, containing 10 M leupeptin, 1 M pepstatin, and 100 M phenylmethylsulfonyl fluoride (PMSF), was included in the buffer. Left ventricular papillary muscles were isolated from the heart and dissected into thin fiber bundles ϳ150 -200 ϫ 1.5-2.0 m in width and length, respectively. Fiber bundles were detergent-skinned overnight in HR solution containing 1% Triton X-100 and the phosphatase inhibitors, calyculin A (0.1 g/ml) and okadaic acid (0.2 g/ml). The experimental procedures for measuring force and ATPase activity were as described previously (5, 15) . A computer program (6) was used to calculate the composition of the activating and relaxing solutions. Activating solution contained (in mM) 20 Ca-EGTA, 1.55 potassium proprionate, 6.59 magnesium chloride, 100 BES, 5 sodium azide, 1 DTT, 10 phosphoenolpyruvate, 0.01 leupeptin, 0.001 pepstatin, 0.01 oligomycin, 0.01 PMSF, and 0.01 A2P5. Relaxing solution was identical except it contained (in mM) 20 EGTA, 21.2 potassium proprionate, and 7.11 MgCl2. Preactivating solution contained (in mM) 0.5 EGTA, 19.5 (Fluka) HDTA, 7.11 MgCl2, and 21.8 potassium proprionate. All solutions contained 1.0 mg/ml pyruvate kinase (386 U/mg) and 0.1 mg/ml lactate dehydrogenase (880 U/mg; Sigma, St. Louis, MO). All solutions had an ionic strength of 180 mM, 5 mM free ATP, and 1 mM free magnesium as determined using the methods of Fabiato and Fabiato assuming an apparent stability constant of the Ca 2ϩ -EGTA complex of 10 6.58 (4, 10) . A cocktail of inhibitors, containing 10 M leupeptin, 1 M pepstatin, and 10 M PMSF, was included in all the buffers. To determine the pCa-tension and pCaATPase activity relationships at short (2.0 m) and long (2.3 m) SLs, fiber bundles were sequentially bathed in solutions with pCa values ranging from 4.3 to 8.0.
The ATPase activity of a fiber bundle was measured by a coupled enzyme assay, as described previously (5, 15). The ATPase measurements were carried out in a buffer that included 0.9 mM NADH, 5 mM NaN3, 10 mM phosphoenolpyruvate, 4 mg/ml pyruvate kinase (500 U/mg), and 0.24 mg/ml lactate dehydrogenase (870 U/mg). Myofibrillar ATPase activity in skinned fiber bundles was measured as follows: ATP regeneration from ADP was coupled to the breakdown of phosphoenolpyruvate to pyruvate and ATP, catalyzed by pyruvate kinase, which was linked to the synthesis of lactate, catalyzed by lactate dehydrogenase. The breakdown of NADH, which is proportional to the amount of ATP consumed, was measured by UV absorbance at 340 nm. The ratio of light intensity at 340 nm (sensitive to NADH concentration) and 410 nm (reference signal) was obtained by means of an analog divider. After each recording, the UV absorbance signal of NADH was calibrated with multiple rapid injections of 0.25 nmol ADP (0.025 l of 10 mM ADP) into the bathing solution with a motor-controlled calibration pipette.
Echocardiography. Transthoracic two-dimensional targeted M-mode and pulsed Doppler echocardiography was performed as previously described (8) . To examine changes in diastolic compliance of the LV, E/A ratio of the mitral inflow [ratio of the maximal velocity of LV early filling (E wave) and the maximal velocity of the left atrial contraction (A wave)], and LV isovolumic relaxation time (IVRT), which was measured from the aortic valve closure to the mitral valve opening, was also determined (23) . All calculations were made from at least three consecutive cardiac cycles.
Gel electrophoresis. The separation of the isoforms of the MHC by SDS-PAGE was performed as recently described (22) . Densitometry was performed to quantify the relative MHC isoform content using the ImageJ open-source software (v1.33 NIH). Data are expressed as the percent ␣-MHC expressed.
Statistics. Data from the normalized Ca 2ϩ -tension and Ca 2ϩ -ATPase activity measurements were fitted to the Hill equation
} by using nonlinear least-squares regression to obtain the EC50 (k) and the Hill coefficient (nH). All data are expressed as means Ϯ SE unless otherwise stated in the figure legend. Student's unpaired t-test was used to determine differences between two groups. Differences among groups larger than two were determined by one-way ANOVA. Student-Newman-Keuls was used for post hoc analysis. Across all data, P value Յ0.05 indicated a statistical significance.
RESULTS

Systolic and diastolic function in PKC vs. wild-type mice.
LV dysfunction is depicted in the representative M-mode echocardiogram in Fig. 1A , which shows that the PKCε mice not only display marked septal and posterior wall hypokinesis, but they also have higher systolic and diastolic dimensions, consistent with increased volumes of the dilated ventricle. Importantly, the left atria of the PKCε hearts were invariably calcified and markedly enlarged (Fig. 1B) , which led us to question the effectiveness of the atrial component of ventricular filling. Diastolic dysfunction may also be masked in the dilated ventricle, so examination of LV filling was important. In Fig. 1C , the pulsed-wave Doppler images indicate that there is no diastolic dysfunction across groups, as measured by the E/A ratios. There was no significant difference in the E/A ratios between groups (E/A ratio 1.13 Ϯ 0.27 vs. PKCε 1.37 Ϯ 0.29, P ϭ 0.34). The A-component of the E/A ratio, which indicates the velocity of blood flow during atrial contraction, was similar [wild-type (WT) A 0.32 Ϯ 0.06 m/s vs. PKCε A 0.31 Ϯ 0.06 m/s, P ϭ 0.66] between groups, suggesting that the calcification did not compromise the atrial contribution to LV filling. Another measure of diastolic function, the LV IVRT, was also not significantly different (IVRT WT 26.0 Ϯ 4.4 and PKCε 27.7 Ϯ 6.1, P ϭ 0.72). Pseudonormalization of the E/A ratio in the PKCε mice could not be ruled out using these echocardiographic techniques (3), but is unlikely in the absence of marked increased end-diastolic pressure (Fig. 2) .
Effect of Dob on contractile reserve. We previously showed compromised systolic pressure development in these animals, but whether activating the ␤-adrenergic system at this stage of failure could augment the systolic effort was speculative. Figure 2A shows representative pressure-volume loops from WT animals before and after the treatment with the ␤-agonist Dob. With Dob treatment, the WT animals responded with a significant increase in LV end-systolic pressure (control 97.6 Ϯ 0.9 vs. Dob 111.7 Ϯ 3.9, P Ͻ 0.001). The contractility was also significantly increased, as measured by E max (Fig. 2C ) and the first derivative of pressure development (ϩdP/dt; Fig.  2D ). In Fig. 2B , the pressure-volume loops from the PKCε animals show a lack of effect of Dob treatment on pressurevolume loop contour and LV systolic pressure (control 78.6 Ϯ 2.6 vs. Dob 83.5 Ϯ 2.3, P Ͼ 0.05). However, there were small, but significant, increases in the E max (Fig. 2C ) and ϩdP/dt (Fig.  2D) . Moreover, the increases in contractility seen in the PKCε animals were considerably smaller than the changes seen in the WT animal. Figure 3A shows that even in the context of increased contractility, the PKCε animals were unable to increase the CO significantly. Of note, the CO measured by the conductance catheter after parallel conductance adjustment was similar to that calculated by aortic dimensions with echocardiography (data not shown). An important observation was that the heart rate before and after treatment with Dob was not different (Fig. 3C) between groups, indicating that this effect is not the result of differences in ␤-adrenoceptor signaling.
Effect of PKC on length-dependent (F-S mechanism) activation. We hypothesized that the PKCε heart would also demonstrate a compromised F-S mechanism given the lack of augmentable CO in the context of increased LV volumes. Figure 4 shows the results from examining the length dependence of Ca 2ϩ -activated tension development (i.e., the myofilament correlate to F-S mechanism) in skinned cardiac muscle preparations. The change in the half-maximal Ca groups were particularly sensitive to length changes over a range of physiological Ca 2ϩ concentrations indicating robust Starling excursion at the myofilament level in these hearts. The EC 50 and Hill coefficient (i.e., measure of thin filament cooperativity) at both SL were also similar between groups ( Table 1) .
Effect of PKC on maximal tension, ATPase, and the economy of tension development. Figure 5 shows that the nonnormalized tension developed over the range of Ca 2ϩ concentrations was significantly diminished in the PKCε compared with WT at short (Fig. 5A) and long (Fig. 5B ) SLs. Indeed, the maximal tension and ATPase activity in PKCε mice were both significantly depressed (30 and 50%, respectively) at short and long SL (Table 1) . We examined the effect of PKCε overexpression on the economy of tension development (tension cost) by simultaneous measurement of myofibrillar ATPase rate and steady-state tension development. Figure 5 , C and D, shows that the PKCε mice used significantly less ATP per unit tension developed at both SL and over the entire range of Ca 2ϩ concentrations. The tension cost, which is the slope of the tension-ATPase relationship, was 32% lower in the PKCε mice compared with the WT controls at short SL (tension cost WT 7.9 Ϯ 0.7 vs. PKCε 5.4 Ϯ 0.7, P ϭ 0.03; Fig. 5C, inset) and 39% reduced at the long SL (tension cost WT 7.5 Ϯ 1.1 vs. PKCε 4.6 Ϯ 0.6, P ϭ 0.03; Fig. 5D, inset) .
MHC expression. We previously showed that the PKCε mice display increased MHC isoform switching that was not attributable to aging (8) . Because MHC content affects the economy of tension, it was important to quantify changes in MHC isoforms in the 12-mo-old animals. Densitometric analysis of the bands from SDS-PAGE of the myofibrillar preparations from the hearts used in these experiments corresponding to ␣-and ␤-MHC shows that the ␣-MHC protein content in PKCε mice makes up only 40% of total (60% ␤-MHC) in the PKCε mice, whereas ␣-MHC content was ϳ85% (15% ␤-MHC) in the WT animals (Fig. 6A) . However, there was only a fair correlation between ␣-MHC content and decreasing tension cost (r ϭ 0.72; Fig. 6B ). Furthermore, the actual tension cost in the PKCε mice was lower than the predicted tension cost (i.e., tension cost ϭ ␣-MHC ϫ ␣-fraction ϩ ␤-MHC ϫ ␤-fraction). Together, these observations suggested that some non-cross-bridge-related phenomenon was also affecting overall tension cost in the PKCε animals.
DISCUSSION
We examined two principal mechanisms that the heart uses to augment CO in a model of DCM that develops as a consequence of targeted PKC overexpression. In this DCM model, we demonstrate preserved length-dependent activation at the myofilament level, but apparently limited Starling curve excursion of the dilated ventricle in the intact animal. Moreover, we provide evidence that a long-term effect of PKCε in the transition to decompensated failure is to enhance contractile efficiency in exchange for reduced CO and contractile reserve. This mechanism may represent a previously speculated physiological role for PKC-mediated myofilament phosphorylation during beat-to-beat regulation. Our data support the idea that the cardiac myofilaments serve as a final point of convergence for altered cellular function in heart failure.
Costs and benefits of submaximal myofilament activation. One of the principal ways in which CO is augmented is through increases in Ca 2ϩ -induced recruitment of contractile units (25) . An important finding of this study was that chronic, unchecked PKCε activity appeared to offset the increase in recruited contractile units due to ␤-stimulation. This occurred in the presence of apparently intact adrenergic signaling, as suggested by analogous heart rate responses to Dob stimulation in the WT and PKCε groups. Moreover, there were no changes in the Ca 2ϩ handling proteins in this model, as previously shown by our group and others (4, 8, 19) . Still, it must be underscored that there was severely diminished contractile activity even at saturating levels of Ca 2ϩ (i.e., Ͼ10 mM) in the skinned preparations. This indicates that even if Ca 2ϩ levels could increase in the intact myocardium, recruitment of more contractile units would not further increase pressure development or CO. Thus simply overexpressing PKCε, as is done here, is not sufficient to cause the well-appreciated downregulation of ␤-receptors or compromised Ca 2ϩ handling commonly observed in naturally occurring cardiac failure. This model, however, demonstrates the progression of a primary myofilament contractilopathy, which is sufficient to lead to dilated pump failure at its end point and supports a role for myofilament phosphorylation in the development of failure.
We showed that not only are the maximum tension and ATPase markedly depressed but they are both also depressed over the entire range of Ca 2ϩ concentrations in the PKCε mice. The decrease in tension development is most likely due to PKCε-mediated phosphorylation, as nearly complete substitution of the MHC complement with the slower ␤-isoform does not affect peak tension (21) . Exactly how prolonged PKCε-mediated phosphorylation causes myofilament contractilopathy is not certain. However, we previously showed that PKCmediated phosphorylation of troponin I and troponin T depresses myofilament activity and that the targeted regions on the thin filament are exquisitely sensitive to charge changes (14 -16) . It is likely that this phosphorylation-dependent charge effect maintains the thin filament in a submaximal orientation. This, in turn, hinders full excursion of the thin filament regulatory unit and precludes actin and myosin from achieving the most favorable interaction. Fig. 3 . A: cardiac output. B: maximal pressure developed. C: heart rate (HR) before and after Dob in both groups. HR was not different across groups before and after Dob, indicating intact adrenergic signaling. Data are expressed as means Ϯ SE. *P Ͻ 0.05, compared with WT control. †P Ͻ 0.05, compared with PKCε control; n ϭ 6 for WT and n ϭ 6 for PKCε. concentrations over the physiological range were used and expressed as M (10 Ϫ6 M). Inset: change in effective Ca 2ϩ concentration (⌬EC50) with increased SL in WT and PKCε (⌬EC50 WT 0.215 Ϯ 0.36 vs. PKCε 0.158 Ϯ 0.039, P ϭ 0.31, 2-tailed t-test; n ϭ 7 WT and n ϭ 6 for PKCε). Data were fitted to the Hill equation to obtain the EC50 and Hill n (see Table 1 ). Another important finding of the current study was the increased economy of tension generation in the PKCε mice. This was surprising in the context of significantly increased EDVs and depression in both myofilament tension and ATPase. The economy difference was largely attributed to the dramatic increase in the ␤-MHC in the PKCε mice, an alteration shown to change economy (21) . However, the measured tension cost in these experiments was lower than predicted from an MHC shift alone and suggested that some non-cross-bridge-related process was affecting tension cost. This suggests a possible role for PKCε-mediated phosphorylation in altered efficiency in this study. Of note, Pyle et al. (20) showed that modulation of the level of phosphorylation of troponin I and troponin T changed the economy of force in young mice with normal, adult MHC ratios. Whatever the exact mechanism for these changes, it appears that the permissive role of the thin filament in the normal heart is amplified in the PKCε-induced myofilament contractilopathy. Similar findings have also been demonstrated in human heart failure (18) .
An interesting question is whether submaximal activation translates into suboptimal activation of the myofilaments. Our data here and elsewhere (14 -16) suggest, in fact, that the opposite is true. We previously theorized that PKCε assumes the physiological role of tempering the contractile machinery in the setting of increased catecholamine release. In the current study, we show direct evidence that this is accomplished through increases in the economy of force development. Our data suggest that PKC is a likely intracellular effector of transiently optimized efficiency, in contrast to PKA, which has no effect on the economy of force (5), but does increase tension cost, slope of ATPase-tension relationship, at short SL (*P Ͻ 0.03 compared with WT). D, inset: tension cost at long SL (*P ϭ 0.04 compared with WT). Data were analyzed using 2-tailed t-test and Levene's test for equality of variances; n ϭ 7 for WT, n ϭ 8 for PKCε at both SLs. Fig. 6 . A: densitometric analysis of SDS-PAGE from homogenized muscle preparations indicated significance from 3 separate preparations for both groups (*P Ͻ 0.05 compared with WT). B: correlation of tension cost with change in myosin heavy chain (MHC) content between the WT (F) and PKCε (OE) groups; r ϭ 0.72. Data are expressed as means Ϯ SE; n ϭ 6 for WT and n ϭ 7 PKCε. cellular ATP usage (9, 26) . Indeed, it is attractive to postulate that during sympathetic norepinephrine release, the ␣-receptor signaling (i.e., PKC) tempers the economics of contraction without counteracting the increased Ca 2ϩ activation via the ␤-receptor (i.e., PKA).
PKC and the F-S mechanism. The activity of the myofilaments and therefore the performance of the myocardium at any given level of Ca 2ϩ are rigidly dependent on the end-diastolic length, the so-called F-S law of the heart. The role of the F-S mechanism in heart failure is debated. Whereas some authors report a compromised F-S mechanism in human failure (24, 28) , others report that this intrinsic property functions normally in humans with failure (10, 29) . In the current experiments, the intact PKCε animals showed a blunted response to changes in EDV. The natural extension of this finding was to confirm these changes using the benchmark measurement of F-S mechanism in skinned muscle, namely the length-dependent Ca 2ϩ activation at the myofilament level. We hypothesized that the length-dependent relationship would also be compromised. However, we demonstrated in this model of end-stage DCM that the cellular correlate to the F-S law was unchanged at the myofilament level. Moreover, we show for the first time that PKCε does not affect the length-sensing ability of the sarcomere.
An explanation for this paradoxical finding lies in the fact that these distinct mechanisms not only coexist on a beat-tobeat basis but are also interdependent (12, 28) . That is to say, decreased Ca 2ϩ -dependent activation can blunt the excursion of the Starling curve and vice versa. This is evidenced in our experiments where the normally functioning cellular F-S mechanism was masked by compromised myofilament effort induced by phosphorylation. The work of Arteaga et al. (1) suggests that the cellular mechanism for the F-S law of the heart is saturable. These authors showed that transgenic hearts expressing the slow skeletal variant of troponin I operate at a high level of Ca 2ϩ sensitivity. However, increased SL in these preparations resulted in significantly smaller increases in Ca 2ϩ sensitivity compared with controls, while synthetic Ca 2ϩ sensitizers were completely ineffective. This is important because the different stages of heart failure, particularly the early compensatory stages, may manifest increased Ca 2ϩ sensitivity, as has been shown in this model (8) . It is plausible that the myofilament mechanism in other forms of failure could be masked by the preexisting increased myofilament Ca 2ϩ sensitivity. The myocardium would therefore be unable to mount a full response to increased stretch and manifest as a blunted F-S mechanism.
In conclusion, unchecked expression of PKCε causes a primary myofilament contractilopathy that, over time, is sufficient to lead to end-stage dilated cardiac failure. The mechanism by which PKCε does this is phosphorylation-induced suppression of the contractile effort, which also obscures the normally functioning Starling mechanism in the beating myocardium. A possible physiological role for PKCε is tempering contractile economy by maximizing the tension produced per cross bridge. This role may be exploited by the compensating, loaded myocardium but ultimately exacerbates pump failure. Despite advances in current therapy for cardiac failure, millions of individuals remain in persistent, ultimately worsening failure. It follows that a rational drug design that directly or indirectly targets the site(s) of phosphorylation at the myofilament level (i.e., troponin I or troponin T), thus altering the covalent charge change, could provide the next generation of effective heart failure drugs. Indeed, drugs, such as the myofilament Ca 2ϩ sensitizer levosimendan, have demonstrated that myofilament targeting is not only feasible but efficacious (27, 30) .
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